Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, consequently, resistance to therapy remains a serious clinical problem. To study the underlying mechanisms, we induced therapy resistance in pati...

Full description

Saved in:

Bibliographic Details
Published in:	JNCI : Journal of the National Cancer Institute Vol. 108; no. 11
Main Authors:	Ter Brugge, Petra, Kristel, Petra, van der Burg, Eline, Boon, Ute, de Maaker, Michiel, Lips, Esther, Mulder, Lennart, de Ruiter, Julian, Moutinho, Catia, Gevensleben, Heidrun, Marangoni, Elisabetta, Majewski, Ian, Józwiak, Katarzyna, Kloosterman, Wigard, van Roosmalen, Markus, Duran, Karen, Hogervorst, Frans, Turner, Nick, Esteller, Manel, Cuppen, Edwin, Wesseling, Jelle, Jonkers, Jos
Format:	Journal Article
Language:	English
Published:	United States 01.11.2016
Subjects:	Animals Antineoplastic Agents - therapeutic use BRCA1 Protein - deficiency Cisplatin - therapeutic use DNA Methylation Drug Resistance, Neoplasm - genetics Female Gene Expression Gene Fusion Genes, BRCA1 Humans Melphalan - therapeutic use Mice Mutation Neoplasm Transplantation Nimustine - therapeutic use Phthalazines - therapeutic use Piperazines - therapeutic use Promoter Regions, Genetic Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics
ISSN:	1460-2105
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!